China NMPA Inspection - National Medical Products Administration - December 03, 2021

This document from the Sichuan Provincial Drug Administration Office, dated December 2, 2021, forwards a directive from the National Medical Products Administration (NMPA). The NMPA's Announcement No. 94 of 2021, originally published on November 30, 2021, mandates the cessation of sales for "Banting Rejuvenating Whitening and Freckle-Removing Cream and Other Cosmetics." The core issue pertains to regulatory non-compliance or potential safety concerns associated with these Banting-branded cosmetic products, which led to the NMPA's decision to halt their market distribution. This action falls under the regulatory authority of the NMPA, with the Sichuan Provincial Drug Administration acting to ensure local enforcement. In response, local Market Supervision Administrations are required to intensify inspections within the cosmetics sector. They must identify and order an immediate stop to the sale of the listed Banting products. Furthermore, these administrations are tasked with thoroughly investigating purchase and inspection records for these items, legally penalizing any illicit activities, and referring any suspected criminal offenses to public security organs. This measure ensures consumer protection and upholds product safety standards across the province.